Inovalon announces launch of InfectionWatch » 07:5805/2705/27/20
Inovalon announced the…
Inovalon announced the launch of InfectionWatch, an infection surveillance and reporting solution that provides healthcare facilities with data-driven insights to empower real-time identification of infections demonstrating antibiotic resistance and virus outbreaks such as COVID-19. This reporting solution helps facilities meet regulatory compliance requirements and empowers them to improve quality outcomes with greater efficiency and confidence. InfectionWatch, a Module of the Inovalon ONE Platform brought to market through the ABILITY provider network, leverages real-time EHR data and predictive analytics to enable seamless monitoring and tracking of infections, providing detailed evaluations of infection trends by category, type and culture organism, as well as predictive insights into patient-specific and infection-specific progressions and risk rates. Additional capabilities of the offering allow provider facilities to track the presence and prevalence of healthcare-acquired infections, community-acquired infections, and "present on admission" infections to identify and recommend appropriate and timely prevention interventions. Leveraging this comprehensive analytical insight, facilities can track targeted infections, identify potential cases of antimicrobial resistance, monitor and report adverse events, and deploy more effective infection control measures.
|Over a week ago|
Fly Intel: Top five analyst initiations » 10:1205/2105/21/20
INOV, RCL, NCLH, CCL, AIMC, MRCY, RVMD
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Inovalon (INOV) was initiated with a Buy at Guggenheim and Benchmark. 2. Royal Caribbean (RCL) and Norwegian Cruise Line (NCLH) were initiated with an Outperform at Credit Suisse while Carnival (CCL) was initiated with a Neutral. 3. Altra Industrial Motion (AIMC) initiated with an Outperform at Oppenheimer. 4. Mercury Systems (MRCY) initiated with a Sector Perform at RBC Capital. 5. Revolution Medicines (RVMD) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Guggenheim starts Inovalon at Buy, sees pullback as attractive opportunity » 08:1605/2105/21/20
As previously reported,…
As previously reported, Guggenheim analyst Glen Santangelo initiated coverage of Inovalon with a Buy rating and $22 price target. While the stock's performance to date in Inovalon's five years as a public company "has been disappointing," the company has benefited from its business model transition with faster revenue growth and a better margin profile over the past couple of years, Santangelo tells investors. He believes the recent COVID-driven pullback presents an attractive entry point to buy the shares, Santangelo added.
Inovalon initiated with a Buy at Guggenheim » 06:1205/2105/21/20
Guggenheim analyst Glen…
Guggenheim analyst Glen Santangelo initiated coverage of Inovalon with a Buy rating and $22 price target.
Fly Intel: After-Hours Movers » 18:3404/2904/29/20
ET, PTON, RIG, HIG, INOV, EBAY, AFL, QCOM, MSFT, PS, VRTX, HCC, NGVT, TSLA, NOW, HOLX, FB, MTSI, UCTT, AR, MTDR, CCS, KRA
Check out this evening's…
Inovalon lowers FY20 EPS guidance to 53c-57c, consensus 59c » 16:3304/2904/29/20
Lowers FY20 revenue…
Lowers FY20 revenue guidance to $672M-$698M, consensus $701.41M.
Inovalon sees Q2 EPS 11c-12c, consensus 14c » 16:3204/2904/29/20
Sees Q2 revenue…
Sees Q2 revenue $157M-$163M, consensus $172.56M.
Inovalon sees Q2 revenue growth 0%-4% year-over-year » 16:3104/2904/29/20
The company's previous guidance was for revenue growth of 9%-12% year-over-year.
Inovalon reports Q1 EPS 11c, consensus 11c » 16:2904/2904/29/20
Reports Q1 revenue…
Reports Q1 revenue $154.2M, consensus $158.96M.
|Over a month ago|
Inovalon initiated with an Outperform at SVB Leerink » 08:5004/1304/13/20
SVB Leerink analyst…
SVB Leerink analyst Stephanie Davis Demko initiated coverage of Inovalon with an Outperform rating and $21 price target. The analyst believes 2020 will be a battleground year for the healthcare landscape on both post-COVID-19 recession fears and headline risk surrounding the election. Given the uncertain macro backdrop, she prefers names benefiting from secular growth trends that will overshadow market volatility, with a high level of revenue visibility and potential for upward estimate revisions in fiscal year 2020, and closest to the consumer, where Davis Demko sees the strongest near-term demand.